Johnson & Johnson is discontinuing two CAR-T programs for B-cell lymphoma, ending work on JNJ-9530 and JNJ-4496 months after the company highlighted the assets as potentially best-in-class. The company said the programs were dropped based on portfolio priorities and an assessment of the evolving treatment landscape. Both candidates were in early clinical development when J&J halted the programs. JNJ will continue supporting patients already in ongoing trials under existing study protocols. The move underscores how CAR-T capital allocation is tightening as oncology shareholders demand clearer differentiation, and as antibody- and bispecific-driven strategies continue to expand within large B-cell lymphoma treatment sequences.